deltatrials
Terminated PHASE1 INTERVENTIONAL 2-arm NCT02669264

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Sponsor: ADC Therapeutics S.A.

Conditions Acute Lymphoblastic Leukemia
Interventions ADCT-402
Updated 17 times since 2017 Last updated: Apr 27, 2021 Started: Mar 31, 2016 Primary completion: Jul 3, 2018 Completion: Jul 3, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was early terminated prior to part 2 because of slow accrual.

Other terminated trials from ADC Therapeutics S.A.

More terminations from ADC Therapeutics S.A.

Other Acute Lymphoblastic Leukemia trials with similar outcome

Browse all Acute Lymphoblastic Leukemia trials

Listed as NCT02669264, this PHASE1 trial focuses on Acute Lymphoblastic Leukemia and remains terminated or withdrawn. Sponsored by ADC Therapeutics S.A., it has been updated 17 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Feb 2018 · 11 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~May 2019 · 6 months · monthly snapshot~May 2019 – ~Oct 2019 · 5 months · monthly snapshot~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2022 — Mar 2022 [monthly]

    Terminated PHASE1

  5. Dec 2021 — Jan 2022 [monthly]

    Terminated PHASE1

▶ Show 12 earlier versions

  1. Jun 2021 — Dec 2021 [monthly]

    Terminated PHASE1

  2. Mar 2021 — Jun 2021 [monthly]

    Terminated PHASE1

  3. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE1

  4. Oct 2019 — Jan 2021 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  5. May 2019 — Oct 2019 [monthly]

    Completed PHASE1

  6. Nov 2018 — May 2019 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  7. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  9. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. Mar 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  11. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ADC Therapeutics S.A.
Data source: ADC Therapeutics S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations